References from scientific journals
Myelodysplastic syndromes: Contemporary review and how we treat.
Gangat N, Patnaik MM, Tefferi A.
Gangat N, et al.
Am J Hematol. 2016 Jan;91(1):76-89. doi: 10.1002/ajh.24253.
Am J Hematol. 2016.
PMID: 26769228
Free article.
Review.
Currently Food and Drug administration (FDA)-approved drugs for the treatment of MDS are not curative and their effect on survival is limited; they include the hypomethylating agents (HMA) azacitidine and decitabine and lenalidomide for MDS with isolated del(5q). ...
Currently Food and Drug administration (FDA)-approved drugs for the treatment of MDS are not curative and their effect on survival is limite â¦
Effects of 5-Aza-2'-deoxycytidine (decitabine) on gene expression.
Seelan RS, Mukhopadhyay P, Pisano MM, Greene RM.
Seelan RS, et al.
Drug Metab Rev. 2018 May;50(2):193-207. doi: 10.1080/03602532.2018.1437446. Epub 2018 Feb 18.
Drug Metab Rev. 2018.
PMID: 29455551
Review.
Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Cogle CR, Scott BL, Boyd T, Garcia-Manero G.
Cogle CR, et al.
Oncologist. 2015 Dec;20(12):1404-12. doi: 10.1634/theoncologist.2015-0165. Epub 2015 Oct 13.
Oncologist. 2015.
PMID: 26463870
Free PMC article.
Review.
Benefits of azacitidine treatment of patients with AML with >30% blasts have also been shown in a recent phase III trial. ...This review presents clinical data supporting the use of injectable azacitidine in MDS and AML and examines the rationale for and results â¦
Benefits of azacitidine treatment of patients with AML with >30% blasts have also been shown in a recent phase III trial. ...This â¦
5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy.
Christman JK.
Christman JK.
Oncogene. 2002 Aug 12;21(35):5483-95. doi: 10.1038/sj.onc.1205699.
Oncogene. 2002.
PMID: 12154409
Review.
Decitabine.
Hackanson B, Daskalakis M.
Hackanson B, et al.
Recent Results Cancer Res. 2014;201:269-97. doi: 10.1007/978-3-642-54490-3_18.
Recent Results Cancer Res. 2014.
PMID: 24756800
Review.
Besides 5-azacytidine (azacitidine, Vidaza), 5-aza-2'-deoxycytidine (decitabine, Dacogen) is the most widely used inhibitor of DNA methylation, which triggers demethylation leading to consecutive reactivation of epigenetically silenced tumor suppressor genes in vitro and i â¦
Besides 5-azacytidine (azacitidine, Vidaza), 5-aza-2'-deoxycytidine (decitabine, Dacogen) is the most widely used inhibitor of DNA me â¦
Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis.
He PF, Zhou JD, Yao DM, Ma JC, Wen XM, Zhang ZH, Lian XY, Xu ZJ, Qian J, Lin J.
He PF, et al.
Oncotarget. 2017 Jun 20;8(25):41498-41507. doi: 10.18632/oncotarget.17241.
Oncotarget. 2017.
PMID: 28489568
Free PMC article.
Review.
Decitabine.
Daskalakis M, Blagitko-Dorfs N, Hackanson B.
Daskalakis M, et al.
Recent Results Cancer Res. 2010;184:131-57. doi: 10.1007/978-3-642-01222-8_10.
Recent Results Cancer Res. 2010.
PMID: 20072836
Review.
The pyrimidine analogs, 5-azacytidine (azacitidine, Vidaza) and its deoxy derivative, 5-aza-2'-deoxycytidine (decitabine, Dacogen, are the most widely used inhibitors of DNA methylation which trigger demethylation leading to a consecutive reactivation of epigenetically sil â¦
The pyrimidine analogs, 5-azacytidine (azacitidine, Vidaza) and its deoxy derivative, 5-aza-2'-deoxycytidine (decitabine, Dacogen, ar â¦
5-Azacytidine/Azacitidine.
Müller A, Florek M.
Müller A, et al.
Recent Results Cancer Res. 2010;184:159-70. doi: 10.1007/978-3-642-01222-8_11.
Recent Results Cancer Res. 2010.
PMID: 20072837
Review.
Azacitidine.
National Toxicology Program.
National Toxicology Program.
Rep Carcinog. 2011;12:56-7.
Rep Carcinog. 2011.
PMID: 21829253
Free article.
No abstract available.
A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome.
Almasri J, Alkhateeb HB, Firwana B, Sonbol MB, Damlaj M, Wang Z, Murad MH, Al-Kali A.
Almasri J, et al.
Syst Rev. 2018 Sep 19;7(1):144. doi: 10.1186/s13643-018-0805-7.
Syst Rev. 2018.
PMID: 30227896
Free PMC article.
BACKGROUND: Hypomethylating agents (HMA), azacitidine, and decitabine are frequently used in the management of myelodysplastic syndromes (MDS). ...CONCLUSIONS: Azacitidine and decitabine are both associated with improved outcomes compared to BSC. ...
BACKGROUND: Hypomethylating agents (HMA), azacitidine, and decitabine are frequently used in the management of myelodysplastic syndro â¦
|